Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 11 de 11
Filter
1.
Psychol Med ; 47(8): 1357-1369, 2017 Jun.
Article in English | MEDLINE | ID: mdl-27998326

ABSTRACT

BACKGROUND: Identifying youth who may engage in future substance use could facilitate early identification of substance use disorder vulnerability. We aimed to identify biomarkers that predicted future substance use in psychiatrically un-well youth. METHOD: LASSO regression for variable selection was used to predict substance use 24.3 months after neuroimaging assessment in 73 behaviorally and emotionally dysregulated youth aged 13.9 (s.d. = 2.0) years, 30 female, from three clinical sites in the Longitudinal Assessment of Manic Symptoms (LAMS) study. Predictor variables included neural activity during a reward task, cortical thickness, and clinical and demographic variables. RESULTS: Future substance use was associated with higher left middle prefrontal cortex activity, lower left ventral anterior insula activity, thicker caudal anterior cingulate cortex, higher depression and lower mania scores, not using antipsychotic medication, more parental stress, older age. This combination of variables explained 60.4% of the variance in future substance use, and accurately classified 83.6%. CONCLUSIONS: These variables explained a large proportion of the variance, were useful classifiers of future substance use, and showed the value of combining multiple domains to provide a comprehensive understanding of substance use development. This may be a step toward identifying neural measures that can identify future substance use disorder risk, and act as targets for therapeutic interventions.


Subject(s)
Adolescent Behavior/physiology , Affective Symptoms/physiopathology , Cerebral Cortex , Depression/physiopathology , Problem Behavior , Reward , Substance-Related Disorders/diagnosis , Adolescent , Cerebral Cortex/diagnostic imaging , Cerebral Cortex/physiology , Cerebral Cortex/physiopathology , Child , Female , Follow-Up Studies , Humans , Magnetic Resonance Imaging , Male , Substance-Related Disorders/diagnostic imaging , Substance-Related Disorders/pathology , Substance-Related Disorders/physiopathology
2.
Acta Psychiatr Scand ; 133(4): 324-34, 2016 Apr.
Article in English | MEDLINE | ID: mdl-26475572

ABSTRACT

OBJECTIVE: Bipolar disorder (BP) frequently co-occurs with other psychiatric disorders. We examine whether course of anxiety disorders (ANX), attention deficit hyperactivity disorder (ADHD), disruptive behavior disorders (DBD), and substance use disorders (SUD) influence likelihood of recovery and recurrence of depression and mania in BP youth. METHOD: Weekly ratings of psychiatric disorder intensity were obtained from 413 participants of the Course and Outcome of BP Youth project, followed for an average of 7.75 years. Multiple-event Cox proportional hazards regression analyses examined worsening of comorbid disorders as predictors of mood episode recovery and recurrence. RESULTS: Increased severity in ANX and SUD predicted longer time to recovery and less time to next depressive episode, and less time to next manic episode. Multivariate models with ANX and SUD found that significant effects of ANX remained, but SUD only predicted longer time to depression recovery. Increased severity of ADHD and DBD predicted shorter time to recurrence for depressive and manic episodes. CONCLUSION: There are significant time-varying relationships between the course of comorbid disorders and episodicity of depression and mania in BP youth. Worsening of comorbid conditions may present as a precursor to mood episode recurrence or warn of mood episode protraction.


Subject(s)
Anxiety Disorders/psychology , Attention Deficit Disorder with Hyperactivity/psychology , Attention Deficit and Disruptive Behavior Disorders/psychology , Bipolar Disorder/psychology , Substance-Related Disorders/psychology , Adolescent , Child , Comorbidity , Female , Humans , Male , Problem Behavior , Psychiatric Status Rating Scales , Risk Factors
3.
Depress Anxiety ; 14(2): 67-78, 2001.
Article in English | MEDLINE | ID: mdl-11668659

ABSTRACT

Current research indicates that there is a strong relationship between pediatric anxiety disorders and depression. Assessment measures show high rates of correlation between depression and anxiety and much of the overlap may be related to a common domain of negative affectivity. Anxious youth and depressed youth share a cognitive style marked by a negative bias in information processing. Anxiety disorders and depression are frequently comorbid in children and adolescents. About 25-50% of depressed youth have comorbid anxiety disorders and about 10-15% of anxious youth have depression. Twin and family studies have demonstrated that pediatric anxiety disorders and depression likely share some common genetic factors or influences. Selective serotonin reuptake inhibitors and cognitive-behavioral therapy have been shown in randomized controlled trials to be efficacious for both pediatric depression and anxiety disorders. Integrating the treatment literature with studies of phenomenology, biology and genetics indicates that pediatric anxiety disorders and depression may share a genetically determined neurobiological component that could involve neural circuits that include or are modulated by serotonergic neurons. This component could contribute to the negative affective temperament that appears to be common in both pediatric depression and anxiety disorders.


Subject(s)
Anxiety Disorders/diagnosis , Depressive Disorder/diagnosis , Adolescent , Anxiety Disorders/genetics , Anxiety Disorders/psychology , Child , Cognitive Behavioral Therapy , Combined Modality Therapy , Comorbidity , Depressive Disorder/genetics , Depressive Disorder/psychology , Female , Genetic Predisposition to Disease , Humans , Male , Personality Assessment , Selective Serotonin Reuptake Inhibitors/therapeutic use
4.
Biol Psychiatry ; 48(10): 981-8, 2000 Nov 15.
Article in English | MEDLINE | ID: mdl-11082472

ABSTRACT

BACKGROUND: This study examined growth hormone (GH) response to growth hormone-releasing hormone (GHRH) in a large sample of depressed children compared with normal control children. Within-subject comparisons were also performed in control subjects to examine test-retest reliability and in depressed children comparing episode versus clinical recovery. METHODS: The sample included depressed children (n = 82) and normal control children (n = 55) group-matched for age, gender, and pubertal status; the mean ages were 11.2 +/- 1.7 and 11.2 +/- 1.8 years, respectively. We gave GHRH (0.1 mcg/Kg) at 9 AM, and serum GH levels were determined every 15 min from -30 min through +90 min of the GHRH infusion. A subgroup of normal control subjects (n = 11) repeated the protocol for test-retest reliability within a 2-month interval. A subgroup of depressed children (n = 20) were restudied off all medications following full clinical remission from depression. RESULTS: The mean GH response to GHRH was significantly lower in the depressed group (8.7 ng/mL +/- SEM 0.9) compared with normal control children [12.2 ng/mL +/- SEM 1.3; t(135) = 2.59, p =.01 effect size 0.44]. The test-retest reliability of GH response to GHRH was stable (intraclass correlation =.93 for mean post-GH). The GH response to GHRH remained low in subjects restudied during clinical remission from depression. CONCLUSIONS: Depressed children show low GH response to GHRH. The measure appears to be reliable, and the low GH response continues following clinical remission. Further studies are needed to explore the mechanism and relative specificity of this finding.


Subject(s)
Depressive Disorder/blood , Growth Hormone-Releasing Hormone/pharmacology , Human Growth Hormone/blood , Child , Depressive Disorder/psychology , Female , Follow-Up Studies , Humans , Male , Psychiatric Status Rating Scales , Reproducibility of Results , Sex Characteristics
5.
Arch Gen Psychiatry ; 57(9): 867-72, 2000 Sep.
Article in English | MEDLINE | ID: mdl-10986550

ABSTRACT

BACKGROUND: Decreased growth hormone (GH) response to pharmacologic stimulation has been found in children and adolescents during an episode of major depressive disorder and after recovery. In this study, we sought to determine whether GH secretion is similarly altered in children and adolescents who had never experienced depression but were at high risk of developing depression. METHODS: Subjects were 8 through 16 years of age and selected for high- and low-risk status according to familial loading for mood disorders. Sixty-four high-risk and 55 low-risk healthy subjects participated in the study, which assessed the following GH measures: (1) GH before growth hormone-releasing hormone (GHRH) infusion, every 15 minutes for 30 minutes; (2) GH response after intravenous infusion of GHRH (0.1 microg/kg), every 15 minutes for 90 minutes; and (3) nocturnal GH every 20 minutes from 9 PM until morning awakening. RESULTS: After stimulation with GHRH, the high-risk subjects secreted significantly less GH compared with the low-risk healthy controls (effect sizes for mean and peak GH, 0.52 [P =.007] and 0.40 [P =.04], respectively). In contrast, there were no between-group differences in the pre-GHRH and nocturnal GH secretion levels. Exposure to recent stressors was not associated with GH secretion. CONCLUSIONS: Taken together with previous evidence of decreased GH after GHRH infusion in acutely depressed and recovered children, these results indicate that the decreased GH response found in high-risk subjects may represent a trait marker for depression in children and adolescents.


Subject(s)
Depressive Disorder/diagnosis , Growth Hormone-Releasing Hormone , Human Growth Hormone/blood , Adolescent , Biomarkers , Child , Depressive Disorder/blood , Depressive Disorder/epidemiology , Family , Female , Growth Hormone-Releasing Hormone/administration & dosage , Growth Hormone-Releasing Hormone/pharmacology , Human Growth Hormone/metabolism , Humans , Infusions, Intravenous , Life Change Events , Male , Mental Disorders/diagnosis , Mental Disorders/epidemiology , Psychiatric Status Rating Scales/statistics & numerical data , Risk Factors , Sleep/physiology
6.
Biol Psychiatry ; 48(1): 51-7, 2000 Jul 01.
Article in English | MEDLINE | ID: mdl-10913507

ABSTRACT

BACKGROUND: The neurodevelopment of childhood anxiety disorders is not well understood. Basic research has implicated the amygdala and circuits related to these nuclei as being central to several aspects of fear and fear-related behaviors in animals. METHODS: Magnetic resonance imaging was used to measure amygdala volumes and comparison brain regions in 12 child and adolescent subjects with generalized anxiety disorder and 24 comparison subjects. Groups were matched on age, sex, height, and handedness and were also similar on measures of weight, socioeconomic status, and full scale IQ. RESULTS: Right and total amygdala volumes were significantly larger in generalized anxiety disorder subjects. Intracranial, cerebral, cerebral gray and white matter, temporal lobe, hippocampal, and basal ganglia volumes and measures of the midsagittal area of the corpus callosum did not differ between groups. CONCLUSIONS: Although these data are preliminary and from a small sample, the results are consistent with a line of thinking that alterations in the structure and function of the amygdala may be associated with pediatric generalized anxiety disorder.


Subject(s)
Amygdala/pathology , Anxiety Disorders/pathology , Anxiety Disorders/psychology , Dominance, Cerebral , Fear , Adolescent , Amygdala/physiopathology , Brain/pathology , Case-Control Studies , Child , Female , Humans , Image Processing, Computer-Assisted , Magnetic Resonance Imaging , Male , Pilot Projects , Psychiatric Status Rating Scales
7.
AJNR Am J Neuroradiol ; 14(4): 907-10, 1993.
Article in English | MEDLINE | ID: mdl-8352163

ABSTRACT

PURPOSE: To evaluate further the clinical utility of the interuncal distance (IUD) measured from axial MR scans as a reflection of hippocampal atrophy. METHODS: The IUD measured from the axial MR scans of 17 healthy control subjects was correlated with the volume of the amygdala hippocampal complex obtained from coronal MR images. The IUD was also measured on axial MR scans in 12 patients with possible or probable Alzheimer disease. RESULTS: The correlation between the total amygdala hippocampal volume and the IUD was insignificant for control subjects (r = -0.38, P = .13). When analysis of covariance was performed with the IUD as the dependent variable and age and diagnosis as the independent variables, overall R2 was 0.25. Age (F = 5.02, df = 1, P = .034), but not diagnosis (F = 0.02, df = 2, P = .88), had a significant effect. CONCLUSIONS: The IUD has no significant correlation with the amygdala hippocampal volume. The IUD appears to be a better measure of overall brain volume, which changes with age. In our patient population diagnosed with mild to moderate Alzheimer disease, the IUD measurement was not found to be useful in distinguishing their scans from those of the volunteers.


Subject(s)
Alzheimer Disease/pathology , Hippocampus/pathology , Adult , Aged , Aged, 80 and over , Atrophy , Female , Humans , Male , Middle Aged , Reference Values
8.
Psychiatry Res ; 47(2): 163-73, 1993 May.
Article in English | MEDLINE | ID: mdl-8341769

ABSTRACT

Hypercortisolemia is a frequently observed abnormality in patients with major depression. It has been hypothesized that the hippocampus, as a major feedback site for glucocorticoids, is involved in the pathophysiology of hypercortisolemia. Some have in fact posited that the hippocampus is marked by diminished size in depressed patients with hypercortisolemia. We tested this hypothesis by examining the relationship between hippocampal volume, assessed with magnetic resonance imaging, and hypercortisolemia using the dexamethasone suppression test (DST) in a group of 19 depressed patients. No differences in hippocampal volume were observed between patients and control subjects (n = 30). Within the patient group, DST suppressors did not differ from DST nonsuppressors in hippocampal volume. However, a relationship between hippocampal volume and 11 p.m. cortisol concentration was observed after covariance adjustment for age and sex. Furthermore, significant negative correlations were observed between hippocampal volume and both age of depressive onset and number of hospitalizations. The results of this study therefore provide limited support for the hypothesis regarding an essential role of the hippocampus in the neuroendocrine elevation of glucocorticoids in depression.


Subject(s)
Depressive Disorder/diagnosis , Hippocampus/pathology , Hydrocortisone/blood , Magnetic Resonance Imaging , Adult , Amygdala/diagnostic imaging , Amygdala/pathology , Depressive Disorder/blood , Depressive Disorder/pathology , Dexamethasone , Female , Humans , Male , Middle Aged , Radiography
9.
Psychiatry Res ; 44(1): 63-70, 1992 Oct.
Article in English | MEDLINE | ID: mdl-1461948

ABSTRACT

The relationship between dexamethasone suppression test (DST) results and in vivo pituitary volume was studied in 24 psychiatric inpatients. The principles of systematic stereology were used to measure pituitary volume from 3-mm contiguous sagittal spin-echo magnetic resonance (MR) images of the brain. There was no correlation between pituitary volume and 3 p.m. or 10 p.m. postdexamethasone (post-DEX) plasma cortisol concentrations. However, when multiple regression analysis was performed to relate pituitary volume to gender, age, and post-DEX plasma cortisol concentrations, there was a significant relationship between pituitary volume and age, gender, and 10 p.m. post-DEX cortisol plasma concentration. This is the first study to demonstrate a method that directly measures, rather than estimates, in vivo pituitary volume. Furthermore, it suggests that activation of the hypothalamic-pituitary-adrenal axis in psychiatric patients, as manifested by elevated post-DEX cortisol concentrations, may influence pituitary volume.


Subject(s)
Depressive Disorder/diagnosis , Dexamethasone , Hydrocortisone/blood , Hypothalamo-Hypophyseal System/physiopathology , Magnetic Resonance Imaging , Pituitary Gland/pathology , Pituitary-Adrenal System/physiopathology , Adult , Circadian Rhythm/physiology , Depressive Disorder/physiopathology , Depressive Disorder/psychology , Female , Humans , Male , Middle Aged , Organ Size/physiology , Regression Analysis
10.
AJNR Am J Neuroradiol ; 13(5): 1295-9, 1992.
Article in English | MEDLINE | ID: mdl-1414818

ABSTRACT

PURPOSE AND METHODS: High-field MR images at 1.5 T were used to characterize the effects of age and gender on pituitary size and shape in a sample of 71 adult volunteers (40 females), aged 21 to 82 years. FINDINGS: For all subjects, age was inversely correlated with pituitary height (r = -.43, P less than .0002) and cross-sectional area (r = -.35, P less than .0028). Age-specific gender differences were also present in pituitary height and area. A convex upper pituitary margin was more common in females (P = .002) and younger subjects (P = .009). CONCLUSIONS: This study confirms that aging is accompanied by gender-specific changes in pituitary size and shape, and provides normative data that may facilitate evaluation of the pituitary gland in neuroendocrine disorders.


Subject(s)
Aging/physiology , Magnetic Resonance Imaging , Pituitary Gland/anatomy & histology , Sex Characteristics , Adult , Aged , Female , Humans , Male , Middle Aged , Reference Values
SELECTION OF CITATIONS
SEARCH DETAIL
...